Bpifrance awards TxCell EUR 1.7 million grant for clinical development of Ovasave

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces the receipt of EUR 1.7 million from Bpifrance.



from The Medical News http://ift.tt/1BjELsr